NCT05348889终止1 期
A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
Chimagen Biosciences, Ltd5 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2022年8月30日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 7
- 试验地点
- 5
- 主要终点
- Escalation: Incidence of Adverse Events
研究概览
简要总结
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
详细描述
This study is an open-label, multicenter, 2-part study of 1A46 in adult patients with advanced relapsed/refractory (r/r) CD20 and/or CD19 positive B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL) who do not have effective standard treatment available. This FIH study will include a dose escalation part and a dose expansion part in 4 cohorts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dose Escalation Part:
- •Aggressive NHL Patients：
- •Aggressive NHL including mantle cell lymphoma and DLBCL histologies, NOS and/or BCL2, BCL6, and or MY B-cell lymphoma with intermediate features between DLBCL, FL grade 3B, and aggressive B-cell lymphoma unclassifiable
- •have previously R-CHOP, R-EPOCH or equivalent anti-CD20 containing therapy
- •with ≥ 2 prior lines of systemic therapy
- •received or ineligible for autologous stem cell transplant (ASCT)
- •have received or been intolerant of all other standard therapies thought to confer clinical benefit.
- •Indolent NHL Patients:
- •including FL of Grades 1-3A and marginal zone lymphoma (MZL)
- •refractory or relapsed after ≥ 2 prior lines of systemic therapy who have received or been intolerant of all other standard therapies thought to confer clinical benefit.
- •Patients must require systemic therapy based on disease-specific criteria.
- •NHL patients should meet the following requirements:
- •The following considerations pertain to prior treatment regimens for NHL:
- •Preinduction salvage chemotherapy and ASCT should be considered 1 therapy.
- •Patients with gastric extranodal MZL, should have failed H. pylori eradication therapy (when H. pylori positive).
- •NHL patients must have expression of CD20 and/or CD19-expression
- •NHL patients in the dose escalation part of the study must have ≥ 1 measurable target lesion as defined by Lugano 2014 criteria ALL Patients：
- •Ph-positive or Ph-negative B-cell ALL refractory to or relapsed after frontline treatment and 1 salvage regimen, have received or been intolerant of all other standard therapies thought to confer clinical benefit. ALL patients should meet the following requirements:
- •Relapsed after or not a candidate for allogeneic SCT.
- •No active acute or chronic graft-versus-host disease for 2 months prior to enrollment and currently receiving no immunosuppressive therapy.
- •persistent CD19 staining of ≥ 50% of blasts.
排除标准
- •Patient has brain metastasis or other significant neurological conditions.
- •Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period.
- •Active serious infection requiring antibiotics within 14 days before study entry.
- •Treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or immunosuppressive medication ≤ 7 days before the first dose of 1A46, with the following exceptions:
- •Topical, ocular, intra-articular, intranasal, or inhalational corticosteroids.
- •Dexamethasone used to reduce peripheral blast counts in ALL patients.
- •Active hepatitis B or C.
- •Known human immunodeficiency virus (HIV) infection.
- •Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.
- •Cerebrovascular accident, transient ischemic attack, myocardial infarction, unstable angina, or New York Heart Association class III or IV heart failure < 6 months of study entry; uncontrolled arrhythmia < 3 months of study entry.
- •Major surgery < 4 weeks or minor surgery < 2 weeks prior to screening.
- •Live virus vaccines < 30 days prior to screening.
- •Inflammatory chronic diseases, or any other diseases the investigator considers can be exacerbated in the setting of immune activation.
- •History of Grade 3-4 allergic reaction to treatment with another mAb, or known to be allergic to protein drugs or recombinant proteins or excipients in 1A46 drug formulation.
- •Concurrent malignancy < 5 years prior to entry other than adequately treated cervical carcinoma in situ, localized squamous cell cancer of the skin, basal cell carcinoma, localized prostate cancer, ductal carcinoma in situ of the breast, or < T1 urothelial carcinoma.
- •History of Grade 3-4 immune-related adverse events (irAEs) or irAEs requiring discontinuation of prior therapies.
- •Pleural effusion, pericardial effusion or ascites requiring frequent drainage or medical intervention.
- •QTc > 480 msec using Fredericia's QT correction formula
- •Patients in the dose escalation part who weigh < 40 kg.
研究组 & 干预措施
Dose Escalation
Experimental
Open label, single arm trial where 1A46 will be administered
干预措施: 1A46 Injection (Drug)
结局指标
主要结局
Escalation: Incidence of Adverse Events
时间窗: Adverse Events are assessed during the first cycle (28 days) in each cohort
To assess the safety and tolerability of 1A46
Escalation: Dose liming toxicity (DLT)
时间窗: DLTs are assessed during the first cycle (28 days) in each cohort
To identify the RP2D and the MTD, if reached
次要结局
- Escalation: Maximum observed concentration (Cmax)(At enrollment and at multiple timepoints until treatment discontinuation, assessed up to 1 year)
- Escalation: Time to reach Cmax (Tmax)(At enrollment and at multiple timepoints until treatment discontinuation, assessed up to 1 year)
- Escalation: Area Under the Concentration-Time Curve (AUC) from Time 0 to t(At enrollment and at multiple timepoints until treatment discontinuation, assessed up to 1 year)
- Escalation: Area under the serum concentration-time curve from time 0 to infinity (AUCinf)(At enrollment and at multiple timepoints until treatment discontinuation, assessed up to 1 year)
- Escalation: Objective Response Rate (ORR)(From Baseline up to end of study or discontinuation due to disease progression, up to 5 years)
- Escalation: Terminal disposition phase half-life(t1/2)(At enrollment and at multiple timepoints until treatment discontinuation, assessed up to 1 year)
- Escalation: Total clearance after IV administration (CL)(At enrollment and at multiple timepoints until treatment discontinuation, assessed up to 1 year)
- Escalation: Anti-drug antibody (ADA)(From Baseline up to end of study or discontinuation due to disease progression, up to 5 years)
- Escalation: Disease control rate (DCR)(From Baseline up to end of study or discontinuation due to disease progression, up to 5 years)
- Escalation: Progression free survival (PFS)(From Baseline up to end of study or discontinuation due to disease progression, up to 5 years)
- Escalation: Overall survival (OS)(From Baseline up to end of study or discontinuation due to disease progression, up to 5 years)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukaemia (ALL)- MARALL - Monoclonal Antibodies In Recurrent B cell ALL (MARALL)This is a phase I/ II trial to determine the efficacy of intravenous veltuzumab and epratuzmab either individually or together in combination with chemotherapy in patients with recurrent acute lymphoblastic lymphoma.MedDRA version: 9.1 Level: LLT Classification code 10003890 Term: B precursor type acute leukaemiaMedDRA version: 9.1 Level: LLT Classification code 10003917 Term: B-cell type acute leukaemiaEUCTR2008-002286-32-GBQueen Mary Medical University of London27
已完成
1 期
Safety and tolerability of the combination of veltuzumab and epratuzumab with intensive chemotherapy in patients with relapsed B-cell acute lymphoblastic leukaemia (ALL)CancerISRCTN15257573Queen Mary University of London27
进行中（未招募）
1 期
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaB-cell Lymphoma RecurrentB-cell Lymphoma RefractoryNCT04304040Beijing InnoCare Pharma Tech Co., Ltd.43
已完成
1 期
B001 in Patients With CD20 Positive B-cell Non Hodgkin's LymphomaCD20 Positive B Cell Non-Hodgkin's LymphomaNCT03332121Shanghai Pharmaceuticals Holding Co., Ltd30
已完成
1 期
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaLymphoma, DiffuseLymphoma, Diffuse, Mixed Lymphocytic-HistiocyticNCT00596804Gilead Sciences39